Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorpheniramine + midazolam
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intranasal, Intravenous, Intradermal
01
Overview
This represents a drug interaction rather than an intentional combination product. Chlorpheniramine is a histamine H1 receptor antagonist used for allergic conditions, while midazolam is a benzodiazepine used for sedation, anxiolysis, and seizure management. When used together, these medications can increase the risk of CNS depression and sedation.
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on chlorpheniramine + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorpheniramine + midazolam.